Drug Trial Radar · NCT01610284
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Last checked: Nov 19, 2026Latest source record: Aug 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,147
Actual
Start
Aug 7, 2012
Primary completion
Apr 29, 2015
Study completion Apr 19, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 4, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal women with hormone Receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative), locally advanced or metastatic breast cancer (MBC) whose disease has progressed on or after aromatase inhibitor (AI) treatment.
Conditions
- Breast Cancer
Interventions
FulvestrantDrug
Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
BKM120Drug
BKM120 100 mg once daily
BKM120 matching placeboDrug
BKM120 matching placebo, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown CohortTime frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to approximately 4 years
Locations
268 sites in 29 countries. Site status is shown where the registry gives one.
University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2)
Mobile, Alabama
Arizona Oncology Associates Dept of Oncology
Phoenix, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
Shapiro and Stafford and Yee and Polanski Study Coordinator
Arcadia, California
Cancer Care Associates Dept.ofCancerCareAssoc.
Fresno, California
St. Jude Heritage Medical Group Virginia Crosson Cancer Center
Fullerton, California
University of California San Diego - Moores Cancer Center UCSD 3
La Jolla, California
Los Angeles Hematology/Oncology Medical Group LA Cancer Network
Los Angeles, California
USC Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisCompCancerCtr (3)
Los Angeles, California
University of California at Los Angeles Dept. of UCLA
Los Angeles, California
Ventura County Hematology and Oncology PMK Medical Group
Oxnard, California
Coastal Integrative Cancer Care
San Luis Obispo, California
Santa Barbara Hematolgy Oncology Medical Group
Santa Barbara, California
Central Coast Medical Oncology Corporation
Santa Maria, California
St Joseph Heritage Healthcare Dept. of RRMG (4)
Santa Rosa, California
Granada Hills Cancer Center
Valencia, California
Kaiser Permanente Northwest Kaiser
Denver, Colorado
Rocky Mountain Cancer Centers RMCC
Greenwood Village, Colorado
Memorial Regional Cancer Center MRCC
Hollywood, Florida
Cancer Specialists of North Florida SC - F2302
Jacksonville, Florida
University of Miami Univ Miami 2
Miami, Florida
MD Anderson Cancer Center - Orlando MD Orlando
Orlando, Florida
Georgia Cancer Specialists SC
Decatur, Georgia
North Shore University Health System
Evanston, Illinois
Cadence Health
Geneva, Illinois
Cancer Care and Hematology Specialists of Chicagoland Niles
Multiple Locations, Illinois
Cancer Center of Kansas CCK
Wichita, Kansas
Mercy Medical Center Mercy Medical SC
Baltimore, Maryland
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med Sidney/John Hopkins
Baltimore, Maryland
Frederick Memorial Hospital Fred. Mem. Hosp.
Frederick, Maryland
Maryland Oncology Hematology, P.A. SC
Rockville, Maryland
Massachusetts General Hospital SC
Boston, Massachusetts
West Michigan Cancer Center Dept of Oncology
Kalamazoo, Michigan
Hematology and Oncology Association at Bridgepoint Hem Onc Bridgepoint
Tupelo, Mississippi
Washington University School of Medicine Regulatory
St Louis, Missouri
Hackensack Meridian Health
Brick, New Jersey
The Valley Hospital / Luckow Pavillion
Paramus, New Jersey
Clinical Research Alliance SC-2
Lake Success, New York
Memorial Sloan Kettering Dept Onc
New York, New York
University of Rochester Medical Center Univ Rochester
Rochester, New York
Showing 40 of 268 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.